Ocugen, Inc. (OCGN)
| Market Cap | 467.16M +128.5% |
| Revenue (ttm) | 4.47M -1.3% |
| Net Income | -71.67M |
| EPS | -0.23 |
| Shares Out | 338.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,308,545 |
| Open | 1.350 |
| Previous Close | 1.340 |
| Day's Range | 1.340 - 1.430 |
| 52-Week Range | 0.800 - 2.725 |
| Beta | 2.31 |
| Analysts | Strong Buy |
| Price Target | 11.43 (+728.26%) |
| Earnings Date | May 5, 2026 |
About OCGN
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under ... [Read more]
Financial Performance
In 2025, Ocugen's revenue was $4.41 million, an increase of 8.83% compared to the previous year's $4.06 million. Losses were -$67.85 million, 25.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for OCGN stock is "Strong Buy." The 12-month stock price target is $11.43, which is an increase of 728.26% from the latest price.
News
Ocugen price target lowered to $11 from $12 at Canaccord
Canaccord analyst Whitney Ijem lowered the firm’s price target on Ocugen (OCGN) to $11 from $12 and keeps a Buy rating on the shares. The firm updated its model following…
Ocugen Transcript: Stifel 2026 Virtual Ophthalmology Forum
Three late-stage gene therapy programs are advancing for major retinal diseases, using master regulator genes to address broad patient populations and unmet needs. Rolling BLA submissions and adaptive trial designs aim for regulatory filings by 2028, supported by strong cash reserves and global market strategy.
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the clos...
Ocugen to Participate in Upcoming May Scientific and Investor Conferences
MALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the...
Ocugen reports Q1 EPS (6c), consensus (5c)
Reports Q1 revenue $1.53M, consensus $358,140. “In the first few months of 2026, we have completed enrollment of two of our late-stage programs and are diligently working toward initiating our…
Ocugen Provides Business Update with First Quarter 2026 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p 30% reductio...
Ocugen Earnings Call Transcript: Q1 2026
Q1 2026 saw major clinical and financial milestones, including a $115M convertible notes offering, positive phase II data in GA, and completed pivotal trial enrollments. Cash runway is projected into 2028, supporting three BLA submissions by 2028.
Ocugen Earnings release: Q1 2026
Ocugen released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Ocugen Quarterly report: Q1 2026
Ocugen has published its Q1 2026 quarterly earnings report on May 5, 2026.
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes
MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen”) (NASDAQ: OCGN) today announced the pricing of $115 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 ...
Ocugen announces private offering of $115M of convertible senior notes
Ocugen (OCGN) announced its intention to offer, subject to market conditions and other factors, $115M aggregate principal amount of convertible senior notes due 2034 in a private offering to qualified...
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes
MALVERN, Pa., May 04, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced its ...
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results
MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that i...
Ocugen Proxy statement: Proxy filing
Ocugen filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Ocugen Proxy statement: Proxy filing
Ocugen filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Ocugen to Present at April 2026 Investor and Industry Conferences
MALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that D...
Ocugen Proxy statement: Proxy filing
Ocugen filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Ocugen Proxy statement: Proxy filing
Ocugen filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Ocugen completes dosing in GARDian3 trial
Ocugen (OCGN) announced that dosing has been successfully completed ahead of schedule in the Phase 2/3 GARDian3 pivotal confirmatory clinical trial for OCU410ST-a modifier gene therapy candidate devel...
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
MALVERN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that d...
Ocugen price target raised to $12 from $8 at Noble Capital
Noble Capital raised the firm’s price target on Ocugen (OCGN) to $12 from $8 and keeps an Outperform rating on the shares after the company reported Phase 2 data for…
Ocugen price target raised to $10 from $7 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Ocugen (OCGN) to $10 from $7 and keeps a Buy rating on the shares. The firm cites the Phase…
Ocugen Transcript: Study update
Phase II results for OCU410 in GA showed a 31% reduction in lesion growth at 12 months with a favorable safety profile and significant preservation of photoreceptor structure. The medium dose will advance to phase III, targeting a global enrollment of 300 patients.
Ocugen Press release: Study update
Ocugen issued a press release on March 24, 2026, disclosing material business information to investors.
Ocugen announces 12-month data from ArMaDa clinical trial of OCU410
Ocugen (OCGN) announced 12-month data from the Phase 2 ArMaDa clinical trial evaluating OCU410, its modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration. Key ...